All In Biotech

Drug Trial Radar · NCT05477563

Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease

A Phase 3b Study to Evaluate Efficacy and Safety of a Single Dose of Autologous CRISPR Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (CTX001) in Subjects With Transfusion-Dependent β-Thalassemia or Severe Sickle Cell Disease

Last checked: Nov 19, 2026Latest source record: Mar 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

26

Planned (sponsor's estimate)

Start

Aug 2, 2022

Primary completion

Jun 9, 2027

Study completion Jun 9, 2027

Sponsor

Lead sponsor
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
Sponsor type
Industry
First posted
Jul 28, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 35 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single-dose, open-label study in participants with transfusion-dependent β-thalassemia (TDT) or severe sickle cell disease (SCD). The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) using CTX001.

Conditions

  • Beta-Thalassemia
  • Thalassemia
  • Hematologic Diseases
  • Genetic Diseases, Inborn
  • Hemoglobinopathies
  • Sickle Cell Disease
  • Sickle Cell Anemia

Interventions

  • CTX001Biological

    Administered by intravenous (IV) infusion following myeloablative conditioning with busulfan

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Fetal Hemoglobin (HbF) Concentration Over TimeTime frame: Up to 12 Months After CTX001 Infusion
  2. Total Hemoglobin (Hb) Concentration Over TimeTime frame: Up to 12 Months After CTX001 Infusion

Locations

6 sites in 4 countries. Site status is shown where the registry gives one.

  • New York Presbyterian Hospital - Morgan Stanley Children's Hospital

    New York, New York · Recruiting

  • Levine Children's Hospital - Hematology

    Charlotte, North Carolina · Recruiting

  • TriStar Medical Group Children's Specialists - Pediatric Oncology

    Nashville, Tennessee · Recruiting

  • University Hospital Dusseldorf - Department of Pediatric Oncology, Hematology and Clinical Immunology

    Düsseldorf, Germany · Recruiting

  • IRCSS Ospedale Pediatrico Bambino Gesu - Dipartimento di Onco-Ematologia e Terapia Cellulare e Genica

    Rome, Italy · Recruiting

  • King Faisal Specialist Hospital & Research Centre - Riyadh - Hematology

    Al Mathar Ash Shamali, Saudi Arabia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.